Prosecution Insights
Last updated: November 04, 2026
Application No. 18/782,685

TWO-STAGE MICROPARTICLE-BASED THERAPEUTIC DELIVERY SYSTEM AND METHOD

Non-Final OA §DP
Filed
Jul 24, 2024
Priority
Feb 18, 2016 — provisional 62/296,599 +5 more
Examiner
LAZARO, DOMINIC
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Privo Technologies Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
430 granted / 674 resolved
+3.8% vs TC avg
Strong +31% interview lift
Without
With
+31.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
36 currently pending
Career history
708
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
45.4%
+5.4% vs TC avg
§102
9.4%
-30.6% vs TC avg
§112
27.2%
-12.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 674 resolved cases

Office Action

§DP
DETAILED ACTION Status of Claims Claims 1-11 are currently pending. Claims 1-11 are currently under consideration and are the subject of this Office Action. This is the first Office Action on the merits of the claims. Non-elected claims 12-20 are withdrawn from consideration. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Office Action: Non-Final. Election/Restrictions Applicant’s election of the claims of Group I (claims 1-11) in the response filed on August 10, 2026 (to the April 15, 2026 Requirement for Restriction) is acknowledged. In response to applicant’s election, the claims of Group II (claims 12-20) is withdrawn from further consideration pursuant to 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant has elected the claims of Group I without traverse. Also in the response dated August 10, 2026, applicant elected, {with/without} traverse, the following species: (i) Chitosan microparticles containing a. cisplatin as the therapeutic agent, and b. sodium tripolyphosphate; and (ii) Further components which are: a. Propylene glycol as the hydration promoter, b. HPMC as the microparticle adhesion inhibitor, c. Sucralose as the microparticle aggregation inhibitor, and d. cisplatin as a free therapeutic agent in the matrix. and identified claims 1-11 as reading on the elected species. Accordingly, the April 15, 2026 Requirement for Restriction is made FINAL, and claims 1-11 are examined as follows. Claim Objections The following claims are objected to because of the following informalities: Claim 2 is objected to because the claim should read: 2. (Original) A system according to claim 1, wherein the composition further includes a compound selected from a group consisting of a hydration promoter, a microparticle adhesion inhibitor comprising hydroxypropylmethylcellulose (HPMC), a microparticle aggregation inhibitor, and combinations thereof. Appropriate correction is required. Claim Rejections - Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-10 of US 10,398,655 B2 to GOLDBERG to Goldberg et al., hereinafter “‘655 Patent,” matured from copending Application No. 15/436,651. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘655 Patent. Claim 2 is anticipated by claim 1 of the ‘655 Patent. Claim 3 is anticipated by claim 2 of the ‘655 Patent. Claim 4 is anticipated by claim 3 of the ‘655 Patent. Claim 5 is anticipated by claim 4 of the ‘655 Patent. Claim 6 is anticipated by claim 5 of the ‘655 Patent. Claim 7 is anticipated by claim 6 of the ‘655 Patent. Claim 8 is anticipated by claim 7 of the ‘655 Patent. Claim 9 is anticipated by claim 8 of the ‘655 Patent. Claim 10 is anticipated by claim 9 of the ‘655 Patent. Claim 11 is anticipated by claim 10 of the ‘655 Patent. Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-5 and 7-9 of US 10,478,403 B1 to GOLDBERG to Goldberg et al., hereinafter “‘403 Patent,” matured from copending Application No. 15/970,513. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘403 Patent. Claim 2 is anticipated by claim 1 of the ‘403 Patent. Claim 3 is anticipated by claim 2 of the ‘403 Patent. Claim 4 is anticipated by claim 3 of the ‘403 Patent. Claim 5 is anticipated by claim 4 of the ‘403 Patent. Claim 6 is anticipated by claim 5 of the ‘403 Patent. Claim 7 is anticipated by claim 1 of the ‘403 Patent. Claim 8 is anticipated by claim 7 of the ‘403 Patent. Claim 9 is anticipated by claim 1 of the ‘403 Patent. Claim 10 is anticipated by claims 8-9 of the ‘403 Patent. Claim 11 is anticipated by claim 1 of the ‘403 Patent. Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-10 of US 11,617,722 B2 to GOLDBERG to Goldberg et al., hereinafter “‘722 Patent,” matured from copending Application No. 16/557,599. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘722 Patent. Claim 2 is anticipated by claim 1 of the ‘722 Patent. Claim 3 is anticipated by claim 2 of the ‘722 Patent. Claim 4 is anticipated by claim 3 of the ‘722 Patent. Claim 5 is anticipated by claim 4 of the ‘722 Patent. Claim 6 is anticipated by claim 5 of the ‘722 Patent. Claim 7 is anticipated by claim 6 of the ‘722 Patent. Claim 8 is anticipated by claim 7 of the ‘722 Patent. Claim 9 is anticipated by claim 8 of the ‘722 Patent. Claim 10 is anticipated by claim 9 of the ‘722 Patent. Claim 11 is anticipated by claim 10 of the ‘722 Patent. Claims 1-11 are rejected on the ground of nonstatutory double patenting over claims 1-5 and 7-8 of US 11,872,319 B2 to GOLDBERG to Goldberg et al., hereinafter “‘319 Patent,” matured from copending Application No. 16/679,764. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘319 Patent. Claim 2 is anticipated by claim 1 of the ‘319 Patent. Claim 3 is anticipated by claim 2 of the ‘319 Patent. Claim 4 is anticipated by claim 3 of the ‘319 Patent. Claim 5 is anticipated by claim 4 of the ‘319 Patent. Claim 6 is anticipated by claim 5 of the ‘319 Patent. Claim 7 is anticipated by claim 1 of the ‘319 Patent. Claim 8 is anticipated by claim 7 of the ‘319 Patent. Claim 9 is anticipated by claim 1 of the ‘319 Patent. Claim 10 is anticipated by claim 8 of the ‘319 Patent. Claim 11 is anticipated by claim 1 of the ‘319 Patent. Claims 1-7, 9 and 11 are rejected on the ground of nonstatutory double patenting over claims 1, 3-4 and 6 of US 11,938,228 B2 to Goldberg et al., hereinafter “‘228 Patent,” matured from copending Application No. 16/241,408. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘228 Patent. Claim 2 is anticipated by claim 1 of the ‘228 Patent. Claim 3 is anticipated by claim 3 of the ‘228 Patent. Claim 4 is anticipated by claim 1 of the ‘228 Patent. Claim 5 is anticipated by claim 1 of the ‘228 Patent. Claim 6 is anticipated by claim 1 of the ‘228 Patent. Claim 7 is anticipated by claims 3-4 of the ‘228 Patent. Claim 9 is anticipated by claim 6 of the ‘228 Patent. Claim 11 is anticipated by claim 6 of the ‘228 Patent. Claims 1-7 and 9-11 are rejected on the ground of nonstatutory double patenting over claims 1, 8, 11, 13,16 and 19 of US 12,589,080 B2 to Goldberg et al., hereinafter “‘080 Patent,” matured from copending Application No. 17/830,078. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the co-pending claims are drawn to a system for delivery of a therapeutic agent comprising a matrix having a first and second opposed surfaces, wherein the matrix is formed by chitosan and a plurality of microparticles. Claim 1 is anticipated by claim 1 of the ‘080 Patent. Claim 2 is anticipated by claim 11 of the ‘080 Patent. Claim 3 is anticipated by claim 8 of the ‘080 Patent. Claim 4 is anticipated by claim 13 of the ‘080 Patent. Claim 5 is anticipated by claim 19 of the ‘080 Patent. Claim 6 is anticipated by claim 16 of the ‘080 Patent. Claim 7 is anticipated by claim 1 of the ‘080 Patent. Claim 9 is anticipated by claim 1 of the ‘080 Patent. Claim 10 is anticipated by claim 1 of the ‘080 Patent. Claim 11 is anticipated by claim 7 of the ‘080 Patent. Allowable Subject Matter Claims 1-11 are drawn to allowable material pursuant to filing terminal disclaimers for the double patenting references indicated above. US 2014/0234212 A1 by Goldberg et al. is noted as a reference of interest as to the closest prior art. To the extent that claims 12-20 could be rejoined, US 10,159,651 (matured from US Appl. No. 15/897,729) would be a reference of interest as to double patenting, and in this respect, claim 12 should be amended to recite “[a] method for manufacturing a therapeutic agent delivery system according to claim 1,” in order to also encompass (i) and (ii) of claim 1. . Conclusion Claims 1-11 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOMINIC LAZARO whose telephone number is (571)272-2845. The examiner can normally be reached on Monday through Friday, 8:30am to 5:00pm EST; alternating Fridays out. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BETHANY BARHAM can be reached on (571)272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DOMINIC LAZARO/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Jul 24, 2024
Application Filed
Aug 26, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778872
Synthesized Molecule of Solketal Esters from Palm Kit Oil and Glycerin for Cosmetic and Agricultural Formulations
2y 9m to grant Granted Nov 03, 2026
Patent 12773475
INJECTABLE MICRO-ANNEALED POROUS SCAFFOLD FOR ARTICULAR CARTILAGE REGENERATION
4y 4m to grant Granted Oct 27, 2026
Patent 12773423
AUTOMATED SYNTHESIS OF POLYMERIC DUAL DRUGS
2y 7m to grant Granted Oct 27, 2026
Patent 12751451
LAUNDERABLE BACTERICIDAL AND VIRUCIDAL FABRIC FINISH
2y 10m to grant Granted Oct 06, 2026
Patent 12746205
Method for Controlled Release Oral Drug Delivery
2y 6m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
95%
With Interview (+31.2%)
3y 2m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 674 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month